NDNeville R. Dossabhoy

Neville R. Dossabhoy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neville R. Dossabhoy has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Testing in the Management of Adult CKD

    by Fouad T. Chebib, Xiangling Wang, Suneel M. Udani, Maggie Westemeyer, Dinah Clark, Zhiji Zhang, Michelle S. Bloom, Hila Milo Rasouly, Victoria Kolupaeva, Mohammad R. Mizani, et al.

    Key Points: Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy. Background: CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing. Methods: The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point. Results: In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding. Conclusions: Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.


  • Open Access

    Individualized Risk of CKD Progression among US Adults

    by Maria Clarissa Tio, Javed Butler, Xiaoqian Zhu, Yoshitsugu Obi, Timothy E. Yen, Kamyar Kalantar-Zadeh, Elani Streja, Neville R. Dossabhoy, Michael E. Hall, Tariq Shafi

    Key Points: A total of 8.42 million US adults have high CKD progression risk, and 4.77 million of them have eGFR >60 ml/min per 1.73 m2. An individual's absolute risk of CKD progression is important in the diagnosis and prognostication of CKD. Background: CKD is currently defined using GFR or albuminuria. This is on the basis of the relative risk of mortality and kidney outcomes compared with a healthy population and does not consider an individual's absolute risk of CKD progression. Methods: Using National Health and Nutrition Examination Survey data from 1999 to 2020, we characterized the individual-level absolute 3-year risk of ≥40% decline in eGFR (ml/min per 1.73 m2) or kidney failure (3-year risk) among US adults. We categorized the 3-year risk and considered ≥5% as high risk. Results: Among 199.81 million US adults, 8.42 million (4%) had a 3-year risk ≥5%, including 1.04 million adults without CKD (eGFR ≥60 and albuminuria <30 mg/g). These high-risk adults without CKD as currently defined had risk factors including hypertension (98%), heart failure (72%), and diabetes (44%). A total of 15.51 million adults had CKD with preserved eGFR (eGFR ≥60 and albuminuria ≥30 mg/g)—3.73 million had a 3-year risk ≥5%, 41% of whom did not have diabetes and thus would not be screened for albuminuria using current screening recommendations. The 3-year risk of CKD progression was low (risk <5%) in 94% of the 5.66 million US adults with CKD stage G3a-A1 (eGFR 45 to <60 and albuminuria <30 mg/g). Conclusions: Assessment of the individual's absolute risk of CKD progression allowed further risk stratification of patients with CKD and identified individuals without CKD, as currently defined, who were at high risk of CKD progression. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_06_18_ASN0000000000000377.mp3


  • Open Access

    External Validation of a Novel Multimarker GFR Estimating Equation

    by Maria Clarissa Tio, Xiaoqian Zhu, Seth Lirette, Andrew D. Rule, Kenneth Butler, Michael E. Hall, Neville R. Dossabhoy, Thomas Mosley, Tariq Shafi

    Key Points: Using multiple markers may improve GFR estimation especially in settings where creatinine and cystatin C are known to be limited. Panel eGFR is a novel multimarker eGFR equation consisting of age, sex, cystatin C, and nuclear magnetic resonance–measured creatinine, valine, and myo-inositol. eGFR-Cr and eGFR-Cr-CysC may underestimate measured GFR, while panel eGFR was unbiased among younger Black male individuals. Background: Using multiple markers may improve accuracy in GFR estimation. We sought to externally validate and compare the performance of a novel multimarker eGFR (panel eGFR) equation among Black and White persons using the Genetic Epidemiology Network of Arteriopathy cohort. Methods: We included 224 sex, race/ethnicity, and measured GFR (mGFR) category–matched persons, with GFR measured using urinary clearance of iothalamate. We calculated panel eGFR using serum creatinine, valine, myo-inositol, cystatin C, age, and sex. We compared its reliability with current eGFR equations (2021 CKD Epidemiology Collaboration creatinine [eGFR-Cr] and creatinine with cystatin C [eGFR-Cr-CysC]) using median bias, precision, and accuracy metrics. We evaluated each equation's performance in age, sex, and race subgroups. Results: In the overall cohort, 49% were Black individuals, and mean mGFR was 79 ml/min per 1.73 m2. Panel eGFR overestimated mGFR (bias: −2.4 ml/min per 1.73 m2; 95% confidence interval [CI], −4.4 to −0.7), eGFR-Cr-CysC underestimated mGFR (bias: 4.8 ml/min per 1.73 m2; 95% CI, 2.1 to 6.7), while eGFR-Cr was unbiased (bias: 2.0 ml/min per 1.73 m2; 95% CI, −1.1 to 4.6). All equations had comparable accuracy. Among Black male individuals younger than 65 years, both eGFR-Cr (bias: 17.0 ml/min per 1.73 m2; 95% CI, 8.6 to 23.5) and eGFR-Cr-CysC (bias: 14.5 ml/min per 1.73 m2; 95% CI, 6.0 to 19.7) underestimated mGFR, whereas panel eGFR was unbiased (bias: 1.7 ml/min per 1.73 m2; 95% CI, −3.4 to 10.0). Metrics of accuracy for all eGFRs were acceptable in all subgroups except for panel eGFR in Black female individuals younger than 65 years (P30: 73.3%). Conclusions: Panel eGFR can be used to estimate mGFR and may have utility among Black male individuals younger than 65 years where current CKD Epidemiology Collaboration equations are biased.


  • Open Access

    #3875 ASSESSING THE 3-YEAR RISK OF 40% EGFR DECLINE OR KIDNEY FAILURE IN THE US POPULATION

    by Maria Clarissa Tio, Xiaoqian Zhu, Yoshitsugu Obi, Timothy Edmund Yen, Michael Hall, Neville Dossabhoy, Tariq Shafi

    Prognostication of CKD progression currently relies exclusively on eGFR and albuminuria and do not consider comorbid conditions. Recently, the Chronic Kidney Disease Prognosis Consortium (CKD-PC) equation was developed to predict the 3-year risk of 40% eGFR decline or kidney failure in the general population [ 1]. The goal of our study was to assess the distribution of this risk in the US population. We included US adults from the 1999-2020 United States National Health and Nutrition Examination Survey (NHANES; N = 51,699). We calculated eGFR using the CKD-EPI 2021 equation and the 3-year risk of 40% eGFR decline or kidney failure using the CKD-PC equation (3-year risk). We categorized the 3-year risk as 2 or albuminuria≥30 mg/g). Among 199.8 million US adults, mean age was 46±15 years, 51% were female, 11% were non-Hispanic Black persons, and mean BMI was 29±6 kg/m2. 71 million (36%) had hypertension and 26 million (13%) had diabetes. Table 1 shows the distribution of 3-year risk across stages of eGFR and albuminuria. Among 26 million US adults with CKD, the 3-year risks were 2). UACR = urine albumin-to-creatinine ratio (mg/g). CKD Staging: No CKD = eGFR≥60 with UACR2). UACR = urine albumin-to-creatinine ratio (mg/g). CKD Staging: No CKD = eGFR≥60 with UACR<30; CKD G1 & G2 = eGFR≥60 with UACR≥30; CKD G3a A1 = eGFR≥45 and <60 with UACR<30; CKD G3a A2 & A3 = eGFR≥45 and <60 with UACR≥30; CKD G3b = eGFR≥30 and <45; CKD G4 & G5 = eGFR<30. 3-Year Risk Categories = calculated using the CKD Prognosis Consortium equation quantifying the 3-year risk of 40% eGFR decline or kidney failure Percentages are row percents.

  • Tunneled Hemodialysis Catheter Removals by Non‐Interventional Nephrologists: The University of Mississippi Experience

    by Tibor Fülöp, Betzaida Rodríguez, Béla A. Kosztaczky, Kamel A. Gharaibeh, Zsolt Lengvárszky, Neville R. Dossabhoy, Mihály B. Tapolyai

    Bedside removal of tunneled hemodialysis catheters (TDC) by noninterventional Nephrologists has not been frequently performed or studied. We performed a retrospective review of bedside TDC removal at the University of Mississippi Medical Center between January, 2010 and June, 2013. We collected data on multiple patients and procedure‐related variables, success, and complications rates. Of the 138 subjects, mean age was 50 (±15.9) years, 49.3% were female, 88.2% African American and 41% diabetics. Site of removal was the right internal jugular (IJ) in 76.8%, the left IJ in 15.2%, and the femoral vein in 8% of patients. Exactly 44.9% of removals took place in the outpatient setting. Main indications for the removal were proven bacteremia in 30.4%, sepsis or clinical concerns for infection in 15.2% of the cases, while TDC was no longer necessary in 52.2% of patients. All removals were technically successful and well tolerated, but we observed Dacron “cuff” separation and subcutaneous retention in 6.5% of the cases. There was a significant association between outpatient removal and cuff retention (p = 0.007), but not with the site of removal or operator experience. In this relatively large mixed cohort of inpatients and outpatients, bedside TDC removal was well tolerated with a minimal complication rate.


  • Diuretics and Bioimpedance‐Measured Fluid Spaces in Hypertensive Patients

    by Mihály Tapolyai, Mária Faludi, Neville R. Dossabhoy, István Barna, Zsolt Lengvárszky, Tibor Szarvas, Klára Berta, Tibor Fülöp

    The authors examined the relationship between thiazide‐type diuretics and fluid spaces in a cohort of hypertensive patients in a retrospective study of 60 stable hypertensive patients without renal abnormalities who underwent whole‐body bioimpedance analysis. Overhydration was greater in the diuretic group, but only to a nonsignificant degree (5.9 vs 2.9%; P=.21). The total body water did not differ in the two groups (41.8 L vs 40.5 L; P=.64). Extracellular fluid volume (ECV) (19.7 L vs 18.5 L; P=.35) and intracellular fluid volume (ICV) spaces (20.8 L vs 21.3 L; P=.75) were also not significantly different in the two groups. The ratio of ICV:ECV, however, appeared different: 1.05 vs 1.15 (P=.017) and the effect was maintained in the linear regression–adjusted model (β coefficient: −0.143; P=.001). The diuretic‐related distortion of ICV:ECV ratio indicates potential fluid redistribution in hypertensive patients, with ICV participating in the process.


  • Safety and Efficacy of Percutaneous Renal Biopsy by Physicians-in-Training in an Academic Teaching Setting

    by Tibor Fülöp, Bereket Alemu, Neville R. Dossabhoy, Justin H. Bain, David E. Pruett, Anita Szombathelyi, Albert W. Dreisbach, Mihály Tapolyai

    Objectives: The safety and efficacy of percutaneous renal biopsy (PKB) are relatively little studied in a training setting. We sought to review our recent experience with bedside PKB in our training program. Methods: We performed a retrospective cohort review of our consecutive 2.5-year renal biopsy experience (May 2007–November 2009) at the University of Mississippi Nephrology Fellowship....


  • Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia

    by Neville R. Dossabhoy, Steven Turley, Rebecca Gascoyne, Mihaly Tapolyai, Karina Sulaiman

    There are limited data on total dose infusion (TDI) using iron dextran in geriatric chronic kidney disease (CKD) patients with iron-deficiency anemia (IDA). Our goal was to evaluate the safety of TDI in this setting. We conducted a retrospective chart review spanning a 5 year period (2002–2007), including all patients with CKD and IDA who were treated with iron dextran TDI. Patient demographics were noted, and laboratory values for creatinine, hemoglobin and iron stores were recorded pre- and post-dose. TDI diluted in normal saline was administered intravenously over 4-6 hours after an initial test dose. One hundred fifty-three patients received a total of 250 doses of TDI (mean ± SD = 971 ± 175 mg); age was 69 ± 12 years and creatinine 3.3 ± 1.9 mg/dL. All stages of CKD were represented (stage 4 commonest). Hemoglobin and iron stores improved post-TDI (P < 0.001). None of the patients experienced an anaphylactic reaction or death. Adverse events (AEs) were noted in 8 out of 250 administered doses (3.2%). The most common AEs were itching, chills and back pain. One hundred and ten doses of high molecular weight (HMW) iron dextran produced 6 AEs (5.45%), whereas 140 doses of low molecular weight (LMW) iron dextran produced 2 AEs (1.43%), a non-significant trend (P = 0.1433 by Fishers Exact Test). Iron dextran TDI is relatively safe and effective in correcting IDA in geriatric CKD patients. Fewer AEs were noted with the LMW compared to the HMW product. LMW iron dextran given as TDI can save both cost and time, helping to alleviate issues of non-compliance and patient scheduling.


  • Which fluid space is affected by ultrafiltration during hemodiafiltration?

    by Mihály B. Tapolyai, Mária Faludi, Tibor Fülöp, Neville R. Dossabhoy, Anita Szombathelyi, Klára Berta

    Ultrafiltration (UF) is a common procedure performed during almost all dialysis sessions. During UF, several liters of fluid are removed; however, what proportion of this fluid is removed from which fluid space could not be clinically measured easily until now; we designed this study to evaluate the fluid spaces most affected by UF. This is a prospective cohort study of 40 prevalent chronic hemodialysis patients receiving thrice weekly hemodiafiltration (HDF). We measured the patients' fluid spaces using a whole-body bioimpedance apparatus to evaluate the changes of fluid spaces before and immediately after the HDF sessions. We recorded the data on fluid spaces, UF volume, and blood pressures. The cohort consisted of 40 prevalent HDF patients, aged 60.0 ± 5.2 years (37.5% men; 27.5% people with diabetes), and body weight 71.03 ± 15.48 kg. Achieved UF was 2.38 ± 0.98 L on HDF (measured fluid overload: 2.35 ± 1.44 L). The extracellular fluid (EC) volume decreased from 16.84 ± 3.52 to 14.89 ± 3.06 L (P < 0.0001) and intracellular fluid (IC) volume from 16.88 ± 4.40 to 16.55 ± 4.48 L (P = 0.45). Although urea volume of distribution remained effectively unchanged (31.38 ± 7.28 vs. 30.70 ± 7.32 L; P = 0.45), the degree of EC volume overload decreased from 13.60% ± 7.30% to 3.83% ± 8.32% (P < 0.0001). The mean arterial pressure also decreased from 122.95 ± 19.02 to 108.50 ± 13.91 mmHg (P < 0.0001). We conclude that source of net fluid loss by ultrafiltration is almost exclusively the EC fluid space. The intracellular fluid space is not significantly affected immediately after HDF.


    • 20 December 2013
      • Vol. 165  (5) , 283-5

    Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.

    by Neville R Dossabhoy, Scott McRight, Bhupinder Sangha, Sarah Khan, Cherinet Adgeh

    We present the case of a 61-year-old Caucasian male veteran who had been on orlistat (120mg dosing) for four years, and had changed to the over-the-counter (OTC) form, Alli (orlistat 60mg), about three months before presentation. He had been experiencing nausea and vomiting for three weeks prior to evaluation. Laboratory studies revealed a serum creatinine of 6.2 mg/dL--his previous renal function having been normal. An ultrasound-guided renal biopsy was performed, which revealed deposition of calcium oxalate crystals in the renal tubules. Orlistat is a popular weight-loss medication. Orlistat-induced oxalate crystal nephropathy has recently been reported in the literature, resulting from the original, patented version. We report a case with the first such complication from the OTC version, Alli - which is a reduced-dose formulation. Our case report highlights that this complication can occur after several years of use of the medication and is not necessarily dose dependant.